SBI Securities’s KalVista Pharmaceuticals KALV Stock Holding History

SBI Securities’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-62	Closed	-$1.25K	–	4152
2026 Q1	$1.25K	Sell	62 -57	-48%	-$919	﹤0.01%	2570
2025 Q4	$1.92K	Sell	119 -14	-11%	-$185	﹤0.01%	2395
2025 Q3	$1.62K	Buy	133 +39	+41%	+$539	﹤0.01%	2504
2025 Q2	$1.06K	Hold	94	–	–	﹤0.01%	2653
2025 Q1	$1.08K	Hold	94	–	–	﹤0.01%	2546
2024 Q4	$796	Buy	+94	New	+$974	﹤0.01%	2716

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SBI Securities's KALV Position: Q2 2026 in Review

SBI Securities sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 62 shares — an estimated $1.25K sold.

SBI Securities first reported a position in KALV in Q4 2024 and held it in 6 quarters. The position peaked at $1.92K in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

SBI Securities reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SBI Securities sold 62 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.25K.
SBI Securities first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 6 quarters.
SBI Securities's KalVista Pharmaceuticals position peaked at $1.92K in Q4 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.